Cytokinetics(US:CYTK) Globenewswire·2025-10-30 15:18Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Cytokinetics, Incorporated due to misleading statements regarding the New Drug Application (NDA) process for aficamten, which may have led to significant investor losses [4][6][8]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in Cytokinetics between December 27, 2023, and May 6, 2025, to discuss their legal rights [1][4]. - There is a deadline of November 17, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Cytokinetics [4]. Group 2: Misleading Statements - Defendants allegedly made materially false statements about the expected approval timeline for aficamten's NDA, claiming it would be approved in the second half of 2025 based on a September 26, 2025 PDUFA date [6]. - The company failed to disclose the risks associated with not submitting a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [6][7]. Group 3: Impact on Investors - Following the revelation of the misleading statements, class members purchased Cytokinetics' common stock at inflated prices and subsequently suffered significant losses when the truth was disclosed [8]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members [9].